Organon & Co. (OGN) is a publicly traded Healthcare sector company. As of October 30, 2026, OGN trades at $13.64 with a market cap of $3.62B and a P/E ratio of 17.48. OGN moved -1.23% today. Year to date, OGN is +85.62%; over the trailing twelve months it is +117.82%. Its 52-week range spans $5.69 to $16.08. Rallies surfaces OGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sun Pharma profit falls on Organon charge as revenue and specialty sales rise: Sun Pharmaceutical Industries’ second-quarter net profit fell to 19.89 billion rupees from 31.18 billion a year earlier after a one-time 12.69 billion rupee charge, largely tied to its planned Organon acquisition and India labour-code provisions. Revenue rose nearly 12% to 161.99 billion rupees, and specialty sales increased 6.9% to $356 million.
| Metric | Value |
|---|---|
| Price | $13.64 |
| Market Cap | $3.62B |
| P/E Ratio | 17.48 |
| EPS | $0.79 |
| Dividend Yield | 0.02% |
| 52-Week High | $16.08 |
| 52-Week Low | $5.69 |
| Volume | 438 |
| Avg Volume | 0 |
| Revenue (TTM) | $6.13B |
| Net Income | $209.00M |
| Gross Margin | 52.69% |
OGN analyst coverage data. Average price target: $0.00.